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Abstract 
Background: The wingless‑type MMTV integration site (Wnt) signaling is a group of signal transduction pathways. 
In canonical Wnt pathway, Wnt ligands bind to low‑density lipoprotein receptor‑related protein 5 or 6 (LRP5 or LRP6), 
resulting in phosphorylation and activation of the receptor. We hypothesize that canonical Wnt pathway plays a role 
in the retinal lesion of age‑related macular degeneration (AMD), a leading cause of irreversible central visual loss in 
elderly.
Methods: We examined LRP6 phosphorylation and Wnt signaling cascade in human retinal sections and plasma 
kallistatin, an endogenous inhibitor of the Wnt pathway in AMD patients and non‑AMD subjects. We also used the 
Ccl2−/−/Cx3cr1−/−/rd8 and Ccl2−/−/Cx3cr1gfp/gfp mouse models with AMD‑like retinal degeneration to further explore 
the involvement of Wnt signaling activation in the retinal lesions in those models and to preclinically evaluate the role 
of Wnt signaling suppression as a potential therapeutic option for AMD.
Results: We found higher levels of LRP6 (a key Wnt signaling receptor) protein phosphorylation and transcripts of the 
Wnt pathway‑targeted genes, as well as higher beta‑catenin protein in AMD macula compared to controls. Kallista‑
tin was decreased in the plasma of AMD patients. Retinal non‑phosphorylated‑β‑catenin and phosphorylated‑LRP6 
were higher in Ccl2−/−/Cx3cr1−/−/rd8 mice than that in wild type. Intravitreal administration of an anti‑LRP6 antibody 
slowed the progression of retinal lesions in Ccl2−/−/Cx3cr1−/−/rd8 and Ccl2−/−/Cx3cr1gfp/gfp mice. Electroretinography 
of treated eyes exhibited larger amplitudes compared to controls in both mouse models. A2E, a retinoid byproduct 
associated with AMD was lower in the treated eyes of Ccl2−/−/Cx3cr1−/−/rd8 mice. Anti‑LRP6 also suppressed the 
expression of Tnf‑α and Icam‑1 in Ccl2−/−/Cx3cr1−/−/rd8 retinas.
Conclusions: Wnt signaling may be disturbed in AMD patients, which could contribute to the retinal inflammation 
and increased A2E levels found in AMD. Aberrant activation of canonical Wnt signaling might also contribute to the 
focal retinal degenerative lesions of mouse models with Ccl2 and Cx3cr1 deficiency, and intravitreal administration of 
anti‑LRP6 antibody could be beneficial by deactivating the canonical Wnt pathway.
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mouse, Ccl2−/−/Cx3cr1gfp/gfp mouse, Serum kallistatin
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Background
Age-related macular degeneration (AMD) is a common 
cause of irreversible central blindness in the elderly [1]. 
Pathological features of AMD include degeneration and/
or atrophy of both photoreceptors and retinal pigment 
epithelia (RPE) in the macula. More advanced stages of 
AMD present as the exudative/neovascular or “wet” form 
featuring choroidal neovascularization (CNV) and the 
geographic atrophy or “dry” form featuring significant 
loss of the photoreceptors and RPE [2]. Even though it 
is known that various pathways such as inflammation, 
apoptosis, and pathological angiogenesis are involved 
during the end stage of the disease [2, 3], the molecular 
mechanisms that lead to the death of photoreceptors and 
other retinal cells in AMD remain poorly understood.
The wingless-type MMTV integration site (Wnt) sign-
aling is a group of signal transduction pathways includ-
ing the canonical pathway, the noncanonical planar cell 
polarity pathway, and the noncanonical Wnt/calcium 
pathway [4]. In the canonical Wnt pathway, Wnt ligands 
bind to frizzled (Fz) receptors or to the coreceptor com-
plex of Fz and low-density lipoprotein receptor-related 
protein 5 or 6 (LRP5 or LRP6), resulting in phosphoryla-
tion and activation of the receptor [5, 6]. Upon activation 
of the receptor, a signaling cascade is triggered, leading 
to attenuation of phosphorylation of transcription fac-
tor β-catenin and its nuclear translocation [4]. Conse-
quently, β-catenin recruits TCF/LEF transcription factors 
in the nucleus and stimulates the expression of Wnt tar-
get genes including CYCLIN D, c-MYC, AXIN 2, VEGF, 
ICAM-1, CTGF, TNF-α, and HIF-1. Improper activation 
of Wnt signaling has been implicated in many patho-
physiological conditions including cancer, neurological 
diseases, and diabetes [4]. Previous reports show that the 
Wnt signaling pathway is activated in the retinas of laser-
induced CNV mouse model, a classic exudative AMD 
model. The therapeutic potential of blocking Wnt signal-
ing by anti-LRP6 antibody in this model was explored [7]. 
However, the role of Wnt signaling in dry AMD has not 
been documented.
We have reported that genetically engineered Ccl2−/−/
Cx3cr1−/− mice on rd8 background (Ccl2−/−/Cx3cr1−/−/
rd8) develop a broad spectrum of dry AMD-like pathol-
ogy with early onset and high penetrance [8–10]. This 
strain exhibits 100  % penetrance and more prominent 
RPE and photoreceptor focal degeneration at an earlier 
age compared to the rd8 mouse with a single base dele-
tion in the Crb1 gene [9, 11]. Although retinal dystro-
phy/dysplasia rd8 lesions were found mainly in the outer 
plexiform layer, this double knockout strain also devel-
ops pathological features similar to human AMD. These 
features included deep focal retinal degeneration, which 
progress with age, photoreceptor thinning and loss, RPE 
alteration, degeneration and atrophy, and A2E accumula-
tion. A few mice also develop CNV. Using this model, we 
have successfully demonstrated beneficial effects of long-
term dietary intake of long chain omega-3 polyunsatu-
rated fatty acids (n-3) and the Age-Related Eye Disease 
Study 2 (AREDS2) diet. We also identified the therapeu-
tic efficiency by using an adeno-associated virus vector 
overexpressing the soluble VEGF receptor gene to trap 
excess VEGFA and recombinant TSG6 protein (an anti-
inflammatory protein produced by mesenchymal stem 
cells) to alleviate the retinal lesions [12–15]. Recently, the 
featured focal dry AMD-like degenerative retinal lesions 
Ccl2−/−/Cx3cr1gfp/gfp mice without rd8 background were 
reported to develop with late-onset, especially after long 
term blue light exposure [16]. This mouse strain also 
developed severe RPE degeneration (Additional file  1: 
Figure S1).
In this study, we examined LRP6 phosphorylation and 
Wnt signaling cascade in human retinal sections and 
plasma kallistatin, an endogenous inhibitor of the Wnt 
pathway in AMD and non-AMD subjects. We also used 
the Ccl2−/−/Cx3cr1−/−/rd8 and the Ccl2−/−/Cx3cr1gfp/gfp 
without rd8 mutation murine models to further explore 
the involvement of Wnt signaling activation in the retinal 
lesions in those models and to preclinically evaluate the 
role of Wnt signaling suppression as a potential thera-
peutic option for AMD.
Methods
Ethics statement
This research adhered to the tenets of the Declaration 
of Helsinki. Each participant provided signed informed 
consent in accordance with protocols for human sub-
ject recruitment and clinical evaluation approved by the 
Institutional Review and Ethics Boards of the National 
Eye Institute. The animal studies were conducted in com-
pliance with the ARVO statement for the use of animals, 
and all animal experiments were performed under proto-
cols approved by the Institutional Animal Care and Use 
Committees of National Eye Institute, National Institutes 
of Health, USA; and Queen’s University Belfast, Belfast, 
UK.
Immunohistochemistry and mRNA expression of human 
ocular sections
Archived paraffin ocular sections from 5 AMD cases (3 
wet, 2 dry) and 5 age-matched normal eyes were sub-
jected to avidin–biotin-complex immunoperoxidase 
staining. Endogenous peroxidase activity was blocked in 
hydrogen peroxide. Polyclonal antihuman goat IgG anti-
bodies against total LRP6 (Cell Signaling Technology, 
Danvers, MA) were applied at a 1:50 dilution for 60 min 
at room temperature. Biotinylated rabbit anti-goat IgG 
Page 3 of 12Tuo et al. J Transl Med  (2015) 13:330 
was used as the linker molecule between the LRP6 anti-
body and avidin–biotin-peroxidase complex for 60  min 
before application of the ABC complex (Vector Lab, 
Mountain View, CA, USA). Diaminobenzidine-hydrogen 
peroxide was used as the chromogen. The sections were 
counterstained with 1 % methyl green. The staining was 
evaluated based the intensity of brown-blackish color on 
the sections. For β-catenin immunohistochemistry, the 
antibody was antihuman rabbit IgG antibody (sc-7199, 
Santa Cruz Biotechnology, Inc. Dallas, TX, USA).
The AMD cases and age-matched normal eyes were 
used for transcript analysis. Neuroretinal and RPE 
cells, Bruch’s membrane and choroidal capillaries in the 
macular area from each ocular section were microdis-
sected for RNA extraction using the Paradise™ Sample 
Quality Assessment Kit (Arcturus Bioscience), followed 
by cDNA synthesis using Invitrogen SuperScript™ II 
reverse transcriptase (Invitrogen, Carlsbad, CA). A260/
A280 of the RNA was greater or equal to 1.80, indicat-
ing that the RNA was pure. Human Total RNA (Life 
Technology, Gaithersburg, MD, USA) was converted to 
cDNA and used as the control for RT-PCR reactions. 
The primers for SYBR Green qPCR were synthesized by 
SABiosciences and supplied in the Real-Time RT-PCR 
Gene Expression Analysis kit (SABiosciences, Frederick, 
MD, USA). Following PCR, a thermal melt profile was 
performed for amplicon identification. Folder changes 
(2−∆∆Ct analysis method) were calculated by comparing 
with Ct values obtained from a paralleled amplification of 
Human Total RNA.
Human plasma for ELISA quantification of Kallistatin
The study group demographics are summarized in 
Table 1. Participant selection and clinical evaluation have 
been previously defined [17–20]. AMD cases were all 
in advanced stages and the controls presented either no 
drusen or fewer than 5 small drusen (<63  µm in diam-
eter) and no signs of other retinal diseases, including but 
not limited to high myopia, retinal dystrophies, central 
serous retinopathy, vein occlusion, diabetic retinopathy, 
or uveitis. The patients and controls were all self-identi-
fied as Caucasian and non-Hispanic.
Kallistatin levels in human plasma were quantified 
by ELISA (R&D Systems, Minneapolis, MN, USA), as 
previously described [21]. Briefly, 96 well microplates 
were coated with mouse anti-human kallistatin capture 
antibody overnight at room temperature (RT). Nonspe-
cific binding to capture antibody was blocking by 1  % 
BSA in PBS at RT for 1 h. Plasma samples were diluted 
(1/20,000) with 1  % BSA in PBS. Samples and stand-
ards were added to wells coated with mouse anti-human 
kallistatin capture antibody. After incubation at RT for 
2 h and the extensive washing with PBS with Tween-20, 
the plate was incubated with 100 μL biotinylated goat 
anti-human kallistatin detection antibody for 2  h, fol-
lowed by incubation with 100 μL Streptavidin conjugated 
to horseradish-peroxidase (R&D Systems) for 20  min. 
After the addition of H2O2/tetramethylbenzidine for 
20 min, 50 μL 2 N H2SO4 was added to stop the reaction. 
Plate was read immediately at 450  nm (VICTOR3  V™ 
Multilabel Counter, PerkinElmer Life And Analytical 
Sciences, Inc, Waltham, MA, USA). The personnel test-
ing the samples were blind to the information and sam-
ples were identified by numeric codes. All measurements 
were performed in triplicate for each sample, and the 
mean values were calculated. Inter- and intra-assay varia-
tions were <5 and 10 %, respectively.
Wnt pathway component mRNA array
Total RNA from mouse retina/RPE was extracted using 
Trizol (Invitrogen, Carlsbad, CA, USA). cDNA was syn-
thesized using reverse transcriptase (Invitrogen). The 
array to identify possible differences in the ocular expres-
sion of Wnt-related genes between Ccl2−/−/Cx3cr1−/−/
rd8 and wild type B6 N mice was performed using Mouse 
WNT Signaling Pathway RT2 Profiler™ PCR Arrays 
according to the manufacturer’s protocols (Qiagen/SABi-
osciences, Gaithersburg, MD, USA). The plate contains 
assays for 92 Wnt pathway associated genes and 4 assays 
to candidate endogenous control genes (Additional file 2: 
Table S1). The reaction was run on an ABI 7500 System 
(Applied Biosystems, CA, USA). Expression values were 
determined with DataAssist™ v2.0 Software (Applied 
Biosystems).
Animals and treatment
The animal study was conducted in compliance with the 
ARVO statement for the use of animals, and all animal 
experiments were performed under protocols approved 
by the Institutional Animal Care and Use Committees 
of National Eye Institute, National Institutes of Health, 
USA and Queen’s University, Belfast, UK. Mice were 
originated and bred from National Eye Institute, National 
Institutes of Health, USA (Ccl2−/−/Cx3cr1−/−/rd8) or 
Queen’s University, Belfast, UK (Ccl2−/−/Cx3cr1gfp/gfp).
The generation of Ccl2−/−/Cx3cr1−/− mice on rd8 
background (Ccl2−/−/Cx3cr1−/−/rd8) and Ccl2−/−/
Cx3cr1−/− without rd8 background (Ccl2−/−/Cx3cr1gfp/
gfp) and their pathological features have been reported 
Table 1 Human plasma samples
Number Average age Male (%) Female Wet Dry
AMD 66 75.7 ± 10.4 28 (42.4) 38 56 10
Control 53 63.4 ± 8.9 15 (28.3) 38 – –
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previously [10, 16]. Specifically, both mouse strains were 
generated as a model of progressive, focal retinal degen-
eration that mimics certain features of human AMD 
lesions, predominant dry AMD phenotype [10, 16]. 
Ccl2−/−/Cx3cr1−/−/rd8 develops retinal lesions sponta-
neously while the retinal lesions in Ccl2−/−/Cx3cr1gfp/gfp 
can be induced by exposing of 3-month old mice to blue 
light (465 nm) for 8 h/day for 6 months. The monoclonal 
anti-LRP6 antibody was obtained using a recombinant 
peptide comprising the E1E2 domain of murine LRP6 
as the antigen [7]. Nonspecific mouse IgG (mIgG) pur-
chased from Vector Laboratories (Burlingame, CA, USA) 
was used as a control for anti-LRP6.
Single injections of 500  ng of anti-LRP6 in 1  μL vol-
ume were intravitreally administered to the right eyes of 
6-week-old Ccl2−/−/Cx3cr1−/−/rd8; the contralateral eye 
was injected with 500 ng of mIgG in the same volume as a 
control (n = 35). The same amount of anti-LRP6 was intra-
vitreally injected once per month into one eye of 6-month-
old Ccl2−/−/Cx3cr1gfp/gfp (i.e. after 3 months light exposure, 
n =  20, 10 for treatment and 10 for control). The control 
eyes were intravitreally given 500  ng (1  μL) mIgG once 
every month. Eyes were harvested at 2  months (Ccl2−/−/
Cx3cr1−/−/rd8) or 3 months (Ccl2−/−/Cx3cr1gfp/gfp) after the 
injection for various measurements. The eyes of C57BL/6N 
with rd8 mutations were used for an assay control.
Fundus photography and scoring
We evaluated the lesion changes by comparing sequen-
tial fundus photographs taken in the same fundus area of 
each eye before the injection and every month after the 
injection using a Karl Storz veterinary otoendoscope [22]. 
Progression was defined as a >10 % increase in the num-
ber of retinal lesions (Score +1), a >50 % increase in the 
lesion size in at least one out of three of the lesions (Score 
+2), more than five fused lesions or the appearance of 
more than two chorioretinal scars (Score +3), and dif-
fuse chorioretinal scars (Score +4) compared to base-
line. Regression was defined as a  >10  % decrease in the 
number of retinal lesions (Score −1), a >50 % decrease in 
lesion size in at least one out of three of the lesions (Score 
−2), a >50 % disappearance of retinal lesions (Score −3) 
or a total disappearance of retinal lesions (Score −4). To 
avoid bias, a masked observer evaluated all fundus pho-
tographs. The lesion scores of each eye were estimated by 
cross-comparison of the same area based on above cri-
teria. Fundus photography taken from the mice tested 
in Belfast site used the topic endoscopic fundus imaging 
(TEFI) system described previously [22, 23].
Electroretinography (ERG)
Light-adapted ERG responses for Ccl2−/−/Cx3cr1−/−/
rd8 were used to evaluate cone-pathway function in the 
retina following a published procedure [24]. Briefly, mice 
adapted to room light were anesthetized with i.p. injec-
tion of a mixture containing ketamine and xylazine. 
Pupils were dilated with 2.5  % phenylephrine (Alcon 
Inc, Fort Worth, TX, USA) and 1 % tropicamide (Alcon 
Inc), and cornea was anesthetized with 0.5  % propa-
racaine (Alcon Inc). Animals were placed on a heating 
pad to maintain body temperature. ERG responses were 
recorded with gold-wire electrodes placed on the center 
of the cornea and measured using a commercial Espion 
E2 system (Diagnosys LLC, Lowell, MA, USA). Light 
emitting diodes with built in ultraviolet (UV) colordome 
provide ganzfeld UV (365  nm) or green (514  nm) light 
stimulus. Photopic ERG responses were recorded in the 
presence of a rod-saturating background of 20 sc cd/
m2. The dark-adapted ERG was recorded for Ccl2−/−/
Cx3cr1gfp/gfp (LKC Technologies, Gaithersburg, MD, 
USA) [25].
Histology
Whole mouse eyes were fixed in 4 % glutaraldehyde-10 % 
formalin and then embedded in methacrylate. The eyes 
were serially sectioned in the vertical pupillary-optic 
nerve plane. Each eye was cut into 6 sections. All sec-
tions were stained with hematoxylin and eosin. If an ocu-
lar lesion was observed, another 6-12 sections were cut 
through the lesion. These slides were also stained with 
Periodic Acid Schiff (PAS) to highlight the Bruch’s mem-
brane and the basement membrane of small neovascular 
vessels.




hexatrienyl]-pyridinium) is the major component of 
lipofuscin fluorophores generated from the visual cycle 
flux of all-trans-retinol. The molecule is particularly cor-
related with retinal aging and AMD pathogenesis [26]. 
A2E was extracted via chloroform/methanol as previously 
described [27]. The extracts dissolved in methanol were sep-
arated by HPLC (Agilent 1100 LC, Wilmington, DE, USA) 
and detected by an ultraviolet detector at a wavelength of 
435 nm. A2E was quantified using external A2E standards 
[28].
Western blot analysis
Western blot analysis detected the phosphorylated level 
of LRP6. Mouse retina was dissected and homogenized 
for protein extraction. Equal amounts (50  μg) of total 
protein from each sample were resolved by SDS poly-
acrylamide gel electrophoresis (SDS-PAGE) and trans-
ferred onto a nitrocellulose membrane. The membrane 
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was blocked with 5  % nonfat milk and separately blot-
ted with primary antibodies (anti-Non-phosphorylated 
β-Catenin, Cell Signaling Technology; anti-phosphoryl-
ated LRP6, Cell Signaling Technology; and anti-LRP6, 
self-made). After thorough washes, the membrane was 
incubated with the peroxidase-conjugated horse anti-
rabbit or horse anti-mouse antibody (Vector Lab). The 
signal was developed with the enhanced chemilumines-
cence (ECL) system (Pierce, Rockford, IL, USA). Mem-
branes were stripped and re-blotted with anti-β-actin 
(Sigma-Aldrich, St. Louis, MO, USA) as the loading con-
trol. Densitometry of the signal bands on digital images 
was quantified using FluorChem Q software (Protein-
Simple, Santa Clara, CA, USA).
Quantification of mRNA expression in mouse eyes 
by RT‑PCR
cDNA synthesis was described as above. The primers/
probes were purchased from Applied Biosystems as 
inventoried TaqMan gene expression reagents. Rela-
tive quantitative real time PCR was performed accord-
ing to ABI’s instructions. To determine the Ct values, the 
threshold level of fluorescence was set manually in the 
early phase of PCR amplification. ABI SDS 1.3.1 software 
and the 2−∆∆Ct analysis method were used to determine 
relative amounts of product using Gapdh as an endog-
enous control. Each sample was analyzed in triplicate.
Statistical analysis
Multiple means were compared by paired T-test. Dif-
ferences were considered significant when p  <0.05. The 
collective ERG amplitudes were calculated by the area 
under curve (AUC) and compared by T-test between the 
groups. Comparison of plasma kallistatin levels between 
AMD patients were performed by independent-samples 
T test.
Results
Aberrant expression of Wnt signaling in human AMD
We examined Wnt signaling in AMD using immunohis-
tochemistry of LRP6 expression in human retinal sec-
tions. More intense immunoreactivity to LRP6 was found 
in the retinal and RPE cells of the macular region of the 
human eyes with AMD compared to normal maculae 
(Fig.  1a). The specificity of the antibody was confirmed 
in cell lysate using a human retinal pigment epithelial 
cell line, ARPE-19 (Additional file 1: Figure S2). Elevated 
mRNA expression of CYCLIN D, C-MYC, AXIN 2 and 
VEGF, which are the target genes of β-catenin, were 
also detected in the AMD macular lesions compared to 
age-matched non-AMD controls (Fig.  1b). Moreover, 
β-catenin protein expression was also higher in the AMD 
macular region (Fig. 1c).
To check the Wnt signaling status in larger number 
of AMD patients, we measured plasma kallistatin, an 
endogenous inhibitor of the Wnt pathway. Demographic 
data of the human subjects are summarized in Table  1. 
Concentrations of kallistatin were significantly decreased 
in the plasma of AMD patients compared to those from 
non-AMD subjects. The averages of kallistatin level 
were 12.67  µg/ml in controls and 10.99  µg/ml in AMD 
group, demonstrating a 13.3 % less in the AMD in com-
parison with the controls (t =  2.104, p =  0.038; Fig.  2). 
There was no correlation between the kallistatin level 
and age in both the AMD and control groups (Additional 
file  1: Figure  S3), which justifies the exclusion of age as 
a cofounder in the statistical analysis. Six AMD plasma 
samples showed higher kallistatin levels, departing from 
the rest of the AMD cluster (Fig. 2). Clinical information 
from these 6 cases did not unveil any common features to 
explain the deviation (Additional file 2: Table S2).
Manipulation of Wnt/β‑catenin is able to rescue the 
AMD‑like lesions of focal retinal degeneration in mouse 
models
To test whether the Wnt/β-catenin is activated in 
Ccl2−/−/Cx3cr1−/−/rd8 mice, the retinal mRNA levels 
of 92 Wnt pathway genes were measured; however, no 
significant differences between the expression of these 
genes in the Ccl2−/−/Cx3cr1−/−/rd8 mice and wild type 
B6  N mice (with rd8 lesions) were found (Additional 
file  1: Figure S4). At the protein level, phosphorylated 
LRP6 (p-LRP6) and non-phosphorylated β-catenin 
(np-b-catenin) were elevated in the retinas of Ccl2−/−/
Cx3cr1−/−/rd8 compared to B6N (Fig.  3a, 3 lanes on 
the left for B6N and 3 lanes in the middle for Ccl2−/−/
Cx3cr1−/−/rd8; Fig. 3b, quantitative analysis), suggesting 
that the Wnt/β-catenin pathway might contribute to the 
AMD-like lesion.
We attempted to intervene in the activation of the 
Wnt signaling pathway by intravitreal administration 
of anti-LRP6 antibody directly into one eye of our two 
mouse models of AMD; the contralateral eye was used as 
sham-injection as a control. Three independent experi-
ments (n = 13 each in the first and second experiments, 
and n  =  9 in the third experiment) were performed in 
Ccl2−/−/Cx3cr1−/−/rd8 and yielded reproducible clinical 
results: funduscopy showed slower progression or allevi-
ation of retinal lesions in the anti-LRP6 antibody-treated 
eyes compared to the control mIgG-injected eyes in 
Ccl2−/−/Cx3cr1−/−/rd8 mice (Fig. 4a), whereas the natu-
ral course of lesion in the model is to worsen over time [8, 
10]. Among 35 pairs of eyes, 26 (74.3 %) were improved, 
8 (22.8 %) stayed the same and 1 (2.9 %) progressed. The 
retinal lesions scores were significantly different between 
the treated and untreated eyes (Fig.  4b). The clinical 
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observation of Ccl2−/−/Cx3cr1gfp/gfp also showed slower 
progression of retinal lesion after the anti-LRP6 antibody 
injection (Fig. 4c), a repeatable data compared to that in 
Ccl2−/−/Cx3cr1−/−/rd8 mice (Fig. 4a).
We used ERG to test functionality differences in 
treated and untreated eyes. Because the retinal lesions of 
Ccl2−/−/Cx3cr1−/−/rd8 are more abundant in ventral ret-
ina (Fig. 4a) where cones preferentially express UV visual 
pigment, we tested UV flash ERG in light-adapted mice. 
Ccl2−/−/Cx3cr1−/−/rd8 mice had lower b wave ampli-
tudes for both UV and green light stimulation than wild 
type B6 N mice (Additional file 1: Figure S5). Two months 
after the anti-LRP6 injection, ERG b-wave amplitudes 
Fig. 1 Wnt signaling molecules in human retina. a Immunochemistry of phosphorylated LRP6 found higher activated LRP6 in the ganglion cell 
layer (brown-blackish staining, arrows) of the retinal sections of AMD maculae (upper panel) than in non‑AMD macular tissues (bottom panel). 
Atrophic/degenerative photoreceptors and abnormal RPE cells are also noted in the macula of AMD specimens (blue circles). These areas also 
illustrate stronger immunoreactivities compared to the normal macula in the lower panel. NFL nerve fiber layer, GCL ganglion cell layer, IPL inner 
plexiform layer, INL inner nuclear layer, OPL outer plexiform layer, ONL outer nuclear layer. b mRNA expression of microdissected macular cells from 
human retinal section was measured by RT‑PCR. Higher expression of CYCLIN D, cMYC, AXIN2, and VEGF was observed in AMD patients compared 
to non‑AMD controls (N = 5, Error bar mean ± SEM); *p < 0.05. c Immunochmistry of β‑catenin in the macula. Higher expression of β‑catenin was 
illustrated in AMD macular region compared to non‑AMD macular area
Fig. 2 Plasma Kallistatin of human samples. The average plasma 
kallistatin levels in AMD patients (n = 66) were decreased compared 
to controls (N = 53, 2 pairs of sample with identical measurements)
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in UV and green light stimulation were enhanced with 
greater improvements under UV light stimulus in 
Ccl2−/−/Cx3cr1−/−/rd8 (Fig. 5 left panel). Even though a 
different ERG protocol was used for Ccl2−/−/Cx3cr1gfp/
gfp, scotopic (dark-adaptation) ERG also exhibited larger 
amplitudes in both a- and b-waves in the treated eyes 
compared to control mIgG treated eyes (Fig.  5 right 
panel).
Histopathologically, the majority of the treated eyes in 
Ccl2−/−/Cx3cr1−/−/rd8 showed stable or improvement of 
retinal lesions 2  months after the injection, which con-
firmed the clinical observation in Ccl2−/−/Cx3cr1−/−/
rd8. Anti-LRP6-treated eyes showed better retinal mor-
phology than that in the mIgG-treated group, charac-
terized by less photoreceptor atrophy, smaller retinal 
lesions, and thicker retinal inner and outer segment lay-
ers (Fig. 6). However, retinal dysplasia caused by rd8 was 
generally unchanged between treated and untreated eyes. 
Histological examination between the treated and con-
trol eyes from 10 pairs of eyes revealed a decreased lesion 
severity in 8 pairs and similar lesion severity in 2 pairs. 
At the biochemical level, A2E was decreased in the anti-
LRP6-treated eyes compared to mIgG-injected controls 
in Ccl2−/−/Cx3cr1−/−/rd8 mice (Fig. 7).
We analyzed the key components of canonic Wnt-β-
catenin signaling in paired retinas that showed a clearly 
improved fundus in the treated eyes when compared to 
control eyes. Western blot analysis indicated that the 
anti-LRP6 antibody suppressed the phosphorylation of 
LRP6 and the dephosphorylation of β-catenin compared 
to the control mIgG treatment, indicating that this anti-
LRP6 antibody blocked the activation of the Wnt signal-
ing pathway (Fig. 3, 3 lanes on the middle and 3 lanes on 
the right).
Quantitative RT-PCR of 5 pairs of Ccl2−/−/Cx3cr1−/−/
rd8 eyes showed decreased Tnf-α and Icam-1 mRNA; 
however, Vegf, Hif-1, Cyclin d, Ctdf, c-myc, and Axin2 
transcripts did not change significantly in the retinal tis-
sue after the anti-LRP6 treatment (Fig. 8).
Discussion
In this study, we found an activated canonical Wnt-β-
catenin signaling pathway in human macular tissue from 
AMD patients and in a murine model with focal retinal 
degeneration. The notion of the involvement of Wnt sign-
aling in AMD is also supported by the systemic decrease 
of kallistatin, an endogenous Wnt signaling antagonist, in 
AMD patients. The blockage of Wnt/β-catenin signaling 
with locally administered anti-LRP6 antibody arrested 
the retinal lesion in two murine models with focal reti-
nal AMD-like lesions. The improvement of the progres-
sive degenerative lesions by histology and retained retinal 
function correlated to suppression of inflammation-
related gene expression, particularly Tnf-α and Icam-1.
Kallistatin is an endogenous anti-angiogenic and anti-
inflammatory factor in the serine proteinase inhibitor 
(SERPIN) family [29–34]. Previous studies have shown 
that kallistatin binds to LRP6 and inhibits Wnt signaling, 
suggesting the Wnt-inhibitory activity is likely respon-
sible for the anti-angiogenic and anti-inflammatory 
Fig. 3 Western blot analysis of key components of the Wnt pathway in mouse retina. a Phosphorylated LRP6 and non‑phosphorylated β‑catenin 
were higher in the retina of Ccl2−/−/Cx3cr1−/−/rd8 compared to wildtype B6N mice. Phosphorylated LRP6 and non‑phosphorylated β‑catenin were 
measured in retinal homogenates of mice treated with the anti‑LRP6 antibody or control mIgG. Reduced phosphorylated LRP6 and non‑phospho‑
rylated β‑catenin were observed after the anti‑LRP6 antibody treatment (n = 3 from each condition). b Quantitative analysis of 3 experiments, *: 
<0.05
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activity of this SERPIN [31, 32]. However, its associa-
tion with AMD patients has not been established. This 
study demonstrated for the first time that kallistatin was 
significantly decreased in the plasma of AMD patients 
compared to non-AMD subjects. While our sample 
set differs substantially in the average ages between the 
AMD and control groups, we did not observe a link 
between the age and the kallistatin levels in both the 
AMD and control groups with correlation analysis, which 
justified the exclusion of age as a confounder in compar-
ing the kallistatin levels between the AMD and controls. 
Decreased kallistatin levels may contribute to Wnt path-
way activation in ocular tissues, leading to inflammation. 
Further studies are needed to evaluate the possible role of 
kallistatin in AMD pathogenesis.
The molecular analysis of mouse retinal tissues indi-
cated that the development of lesions correlated with 
canonical Wnt pathway activation in the retina at the 
post-translational but not the transcriptional level, as we 
did not detect altered mRNA expression of Wnt com-
ponents in an mRNA array but did find altered protein 
phosphorylation of canonical Wnt/β-catenin proteins. 
This finding provided the clue for proper targeting of the 
pathway to manage the retinal lesions. The Wnt pathway 
is known to mediate various physiological and patho-
logical processes including angiogenesis, fibrosis, and 
inflammation [35, 36]. Wnt signaling pathway also shows 
neuroprotective effect during development, such as neu-
ronal migration, synaptic differentiation, mature synapse 
modulation and synaptic plasticity [37–40]. However, 
previous study reported that very limited immunoreac-
tivity in the adult retina, suggesting lower basal level of 
Wnt pathway in adult compared to that in younger retina 
[41]. Those findings also suggest that the Wnt pathway 
Fig. 4 Slower progression or alleviation of retinal lesions in the anti‑LRP6 treated eyes as compared to the control in both models. a Representative 
fundoscopic images of Ccl2−/−/Cx3cr1−/−/rd8. Arrows indicate the yellowish deep retinal lesions. b Comparison of the average retinal lesion scores 
between treated and untreated eyes of 35 Ccl2−/−/Cx3cr1−/−/rd8 mice. Error bar mean ± SEM; *: p < 0.01. c Representative fundoscopic images of 
Ccl2−/−/Cx3cr1gfp/gfp. Arrows indicate the yellowish deep retinal lesions. In Ccl2−/−/Cx3cr1gfp/gfp, only 5 out of 10 treated eyes but 7 out of 10 control 
eyes showed lesion progression
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in adult mice may not be essential for adult neuron sur-
vival. Excessive Wnt signaling activation in certain cell 
types has deleterious effects, including tumorigenesis 
and angiogenesis [42, 43]. Our study also demonstrates 
that overexpression of certain Wnt signaling may worsen 
focal retinal degeneration and AMD lesions.
Fig. 5 ERG of Ccl2−/−/Cx3cr1−/−/rd8 and Ccl2−/−/Cx3cr1gfp/gfp mice. Left panel Averaged photopic b‑wave amplitudes elicited with UV and green 
light flashes from the treated and control eyes in Ccl2−/−/Cx3cr1−/−/rd8. Right panel Serial ERG responses to different intensities of white light flashes 
after dark adaptation were recorded in the treated and control eyes in Ccl2−/−/Cx3cr1gfp/gfp. Data are present as mean ± SEM of 5 mice. *: p < 0.05; 
**: p < 0.01. ***: p < 0.001
Fig. 6 Histology of the Ccl2−/−/Cx3cr1−/−/rd8 mouse retina. Representative histological micrographs: fewer lesions in anti‑LRP6 treated eyes, as 
shown by the reduced loss of photoreceptors and more organized retinal structure. Black arrows indicate degenerative photoreceptors in the OPL 
(top right panel). Red arrows show degeneration and atrophy of ONL and loss of IS/OS in mIgG‑injected group (bottom right panel). Some Crb1‑asso‑
ciated lesions in the OPL are also seen (asterisk, top left panel) (H&E, original magnification, ×200). GCL ganglion cell layer, IPL inner plexiform layer, 
INL inner nuclear layer, OPL outer plexiform layer, ONL outer nuclear layer, IS/OS inner segments/outer segments of photoreceptors
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Multiple Wnt-relevant pathways were activated during 
advanced AMD, when angiogenesis and inflammation 
play important roles [44, 45]. However, a parallel study of 
the above pathways with Wnt cascade in AMD has not 
been well demonstrated. The retinal lesions in the mouse 
models used in this study showed disturbances in angio-
genesis, oxidative stress, apoptosis, and inflammation 
[13, 14, 16, 46–49]. We selected inflammatory (TNF-α 
and ICAM-1), angiogenic (VEGF and HIF), prolifera-
tive (CYCLIN D and c-MYC), oxidative stress (c-MYC), 
fibrotic (CTGF), and Wnt inhibitory (AXIN2) markers 
to determine the molecular profile in AMD. The results 
indicate that the suppression of Wnt signaling mainly 
alters the inflammatory responses.
The Wnt signaling pathway has several intersections 
with other pathways including inflammatory processes 
such as TNF-α and NF-kB signaling [36, 50, 51]. Ccl2−/−/
Cx3cr1−/−/rd8 mice express a spectrum of immunologi-
cal features of AMD, including increased deposition of 
complement factors, altered secretion of chemokines and 
cytokines, and the accumulation of activated microglia 
and macrophages in the retinal lesions [9, 16, 52–54]. 
The inflammatory profile in this strain seems to result 
from the deficiency of Ccl2 and Cx3cr1 rather than the 
rd8 mutation alone [9, 55]. Although we do not have data 
directly linking the Wnt activation with the deficiency of 
Ccl2 and Cx3cr1, the fact that two animal models with 
these two deletions show similar results supports the 
involvement and the importance of Wnt signaling path-
way in AMD pathogenesis.
This study demonstrates that the Wnt pathway activa-
tion is associated with focal retinal degeneration in ani-
mal models and human AMD. Blockage of Wnt signaling 
using a specific antibody for LRP6 improved the retinal 
structure and function, likely through reducing oxidative 
stress and inflammation. Significant lower ocular Tnf-α 
levels have been measured in the Ccl2−/−/Cx3cr1−/−/rd8 
mouse retina treated with omega-3, AREDS2 diet, TSG-
6, PEDF, or Naloxane [12, 14, 15, 46, 47]. This observa-
tion further supports the pathogenic role of the Wnt 
pathway in retinal degeneration in AMD. However, more 
AMD eyes are needed to verify Wnt signaling activity 
and conclude about the pathogenic role of Wnt signaling 
in this disease. Further, kallistatin measurement in AMD 
patients’ plasma is limited by the cross-sectional study. 
A longitudinal prospective study of kallistatin levels in 
different stages of AMD will clarify whether kallistatin 
could be used as a biomarker of AMD. Recently, aqueous 
Wnt signaling modulators, Wnt inhibitory factor 1 (WIF-
1) and Dickkopf 3 (DKK-3) are reported significantly 
higher in neovascular AMD patients, the high WIF-1 
levels are also associated with disrupted length of photo-
receptor inner and outer segments [56]. This finding sup-
ports the implication of Wnt signaling in photoreceptor 
integrity and AMD.
In summary, the balance of Wnt signaling activation 
may disturb homeostasis and allostasis in the normal 
aging retina, which could be linked to AMD pathogen-
esis due to allostatic overload. The activation of canoni-
cal Wnt signaling might contribute to the focal retinal 
degeneration of mouse models with Ccl2 and Cx3cr1 
deficiency, and intravitreal anti-LRP6 antibody therapy 
might be beneficial via deactivation of the canonical Wnt 
pathway.
Fig. 7 Retinal A2E accumulation in the Ccl2−/−/Cx3cr1−/−/rd8 mice. 
Retinal A2E levels in anti‑LRP6 treated and control eyes of Ccl2−/−/
Cx3cr1−/−/rd8. A2E concentrations were determined by HPLC in the 
retina. The A2E level was reduced after anti‑LRP6 antibody injection. 
n = 5 from each group; *: p < 0.05
Fig. 8 mRNA expression of Wnt signaling pathway target genes 
in the treated and control eyes in Ccl2−/−/Cx3cr1−/−/rd8 mice. In 
general, there is lower transcript level in the eyes received anti‑LRP6 
compared to the control eyes measured by quantitative RT‑PCR. *: 
p < 0.05
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Conclusion
This study reported strong evidence of Wnt signaling 
involvement in AMD. A beneficial effect was found on 
retina lesions by intravitreal administration of anti-LRP6 
antibody to deactivate the canonical Wnt pathway in two 
related mouse models with focal retinal degeneration 
mimicking certain features of human AMD.
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Additional file 1: Figure S1. RPE lesion in CCL2-/-CX3CR1gfp/gfp mice. 
Three months old CCL2-/-CX3CR1gfp/gfp mice were exposed to blue light 
(460 nm, 8 h/day) for 6 months. RPE/choroid flatmounts were stained with 
rhodamine‑phalloidin (Red, for F‑actin) and observed by confocal micros‑
copy. The image shows disorganised F‑actin distribution (sign of RPE 
damage) and infiltration of GFP+ macrophages / microglial cells at the 
lesion site. Scale bar = 50 mm. Figure S2. Western blot analysis of LRP6 
expression. The anti‑LRP6 antibody used in immunohistochemistry was 
tested in cell lysate from human retinal pigment epithelia cell line ARPE19. 
Proteins were separated by 8 % SDS‑PAGE gel. Figure S3. Correlation 
analysis between the age and plasma kallistatin level in AMD and control 
subjects. There is no correlation between the age and plasma kallistatin 
level in either AMD or control subjects. Figure S4. A–C: Microarray of 92 
Wnt genes in 3 pairs of eyes (3 mice). The differentiated mRNA expression 
shows no differences in the retina between Ccl2-/-/Cx3cr1-/-/rd8 and B6N 
mice. Figure S5. ERG of Ccl2-/-/Cx3cr1-/-/rd8 and B6N. The b wave ampli‑
tudes are significantly lower in B6N retina compared to Ccl2-/-/Cx3cr1-/-/
rd8 retina under light adapted, UV or green light, indicating damages in 
bipolar, S cone function.
Additional file 2: Table S1.  Gene list of Wnt mRNA Microarray. Table 
S2. The cluster of AMD cases with high kallistatin level.
References
 1. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age‑related macular 
degeneration–emerging pathogenetic and therapeutic concepts. Ann. 
Med. 2006;38:450–71.
 2. Zarbin MA. Age‑related macular degeneration: review of pathogenesis. 
Eur J Ophthalmol. 1998;8:199–206.
 3. Ding X, Patel M, Chan CC. Molecular pathology of age‑related macular 
degeneration. Prog Retin Eye Res. 2009;28:1–18.
 4. MacDonald BT, Tamai K, He X. Wnt/beta‑catenin signaling: components, 
mechanisms, and diseases. Dev Cell. 2009;17:9–26.
 5. Bilic J, Huang YL, Davidson G, Zimmermann T, Cruciat CM, Bienz M, Niehrs 
CM. Wnt induces LRP6 signalosomes and promotes dishevelled‑depend‑
ent LRP6 phosphorylation. Science. 2007;316:1619–22.
 6. MacDonald BT, He X. Frizzled and LRP5/6 receptors for Wnt/beta‑catenin 
signaling. Cold Spring Harb Perspect Biol. 2012;4:1–23.
 7. Hu Y, Chen Y, Lin M, Lee K, Mott RA, Ma JX. Pathogenic role of the wnt 
signaling pathway activation in laser‑induced choroidal neovasculariza‑
tion. Invest Ophthalmol Vis Sci. 2013;54:141–54.
 8. Chan CC, Ross RJ, Shen D, Ding X, Majumdar Z, Bojanowski CM, Zhou M, 
Salem N Jr, Bonner R, Tuo J. Ccl2/Cx3cr1‑deficient mice: an animal model 
for age‑related macular degeneration. Ophthalmic Res. 2008;40:124–8.
 9. Chu XK, Wang Y, Ardeljan D, Tuo J, Chan CC. Controversial view of a 
genetically altered mouse model of focal retinal degeneration. Bioengi‑
neered. 2013;4:130–5.
 10. Tuo J, Bojanowski CM, Zhou M, Shen D, Ross RJ, Rosenberg KI, Cameron 
DJ, Yin C, Kowalak JA, Zhuang Z, et al. Murine ccl2/cx3cr1 deficiency 
results in retinal lesions mimicking human age‑related macular degen‑
eration. Invest Ophthalmol Vis Sci. 2007;48:3827–36.
 11. Zhang J, Tuo J, Cao X, Shen D, Li W, Chan CC. Early degeneration of 
photoreceptor synapse in Ccl2/Cx3cr1‑deficient mice on Crb1(rd8) 
background. Synapse. 2013;67:515–31.
 12. Tuo J, Ross RJ, Herzlich AA, Shen D, Ding X, Zhou M, Coon SL, Hussein 
N, Salem N Jr, Chan CC. A high omega‑3 fatty acid diet reduces retinal 
lesions in a murine model of macular degeneration. Am J Pathol. 
2009;175:799–807.
 13. Tuo J, Pang JJ, Cao X, Shen D, Zhang J, Scaria A, Wadsworth SC, Pechan 
P, Boye SL, Hauswirth WW, et al. AAV5‑mediated sFLT01 gene therapy 
arrests retinal lesions in Ccl2(−/−)/Cx3cr1(−/−) mice. Neurobiol Aging. 
2012;33(433):e410–31.
 14. Tuo J, Cao X, Shen D, Wang Y, Zhang J, Oh JY, Prockop DJ, Chan CC. Anti‑
inflammatory recombinant TSG‑6 stabilizes the progression of focal reti‑
nal degeneration in a murine model. J Neuroinflammation. 2012;9:59–67.
 15. Ramkumar HL, Tuo J, de Shen F, Zhang J, Cao X, Chew EY, Chan CC. 
Nutrient supplementation with n3 polyunsaturated fatty acids, lutein, 
and zeaxanthin decrease A2E accumulation and VEGF expression in the 
retinas of Ccl2/Cx3cr1‑deficient mice on Crb1rd8 background. J Nutr. 
2013;143:1129–35.
 16. Chen M, Hombrebueno JR, Luo C, Penalva R, Zhao J, Colhoun L, Pandi 
SP, Forrester JV, Xu H. Age‑ and light‑dependent development of 
localised retinal atrophy in CCL2(‑/‑)CX3CR1(GFP/GFP) mice. PLoS One. 
2013;8:e61381.
 17. Clemons TE, Milton RC, Klein R, Seddon JM, Ferris FL 3rd. Age‑related 
eye disease study research G: risk factors for the incidence of advanced 
age‑related macular degeneration in the age‑related eye disease study 
(AREDS) AREDS report no. 19. Ophthalmology. 2005;112:533–9.
 18. Age‑Related Eye Disease Study Research G. Risk factors associated with 
age‑related macular degeneration. A case‑control study in the age‑
related eye disease study: age‑related eye disease study report number 3. 
Ophthalmology. 2000;107:2224–32.
 19. Davis MD, Gangnon RE, Lee LY, Hubbard LD, Klein BE, Klein R, Ferris FL, 
Bressler SB, Milton RC. The age‑related eye disease study severity scale for 
age‑related macular degeneration: AREDS Report No. 17. Arch Ophthal‑
mol. 2005;123:1484–98.
 20. Chu XK, Meyerle CB, Liang X, Chew EY, Chan CC, Tuo J. In‑depth analyses 
unveil the association and possible functional involvement of novel 
RAD51B polymorphisms in age‑related macular degeneration. Age 
(Dordr). 2014;36:9627.
 21. Jenkins AJ, McBride JD, Januszewski AS, Karschimkus CS, Zhang B, O’Neal 
DN, Nelson CL, Chung JS, Harper CA, Lyons TJ, et al. Increased serum 
kallistatin levels in type 1 diabetes patients with vascular complications. J 
Angiogenes Res. 2010;2:19.
Page 12 of 12Tuo et al. J Transl Med  (2015) 13:330 
 22. Paques M, Guyomard JL, Simonutti M, Roux MJ, Picaud S, LeGargasson 
JF, Sahel JA. Panretinal, high‑resolution color photography of the Mouse 
Fundus. Investig Ophthalmol Vis Sci. 2007;48:2769–74.
 23. Xu H, Koch P, Chen M, Lau A, Reid DM, Forrester JV. A clinical grading 
system for retinal inflammation in the chronic model of experimental 
autoimmune uveoretinitis using digital fundus images. Exp Eye Res. 
2008;87:319–26.
 24. Chen J, Qian H, Horai R, Chan CC, Caspi RR. Use of optical coherence 
tomography and electroretinography to evaluate retinal pathology in a 
mouse model of autoimmune uveitis. PLoS One. 2013;8:e63904.
 25. Hombrebueno JR, Chen M, Penalva RG, Xu H. Loss of synaptic connectiv‑
ity, particularly in second order neurons is a key feature of diabetic retinal 
neuropathy in the Ins2Akita mouse. PLoS One. 2014;9:e97970.
 26. Ben‑Shabat S, Parish CA, Hashimoto M, Liu J, Nakanishi K, Sparrow JR. 
Fluorescent pigments of the retinal pigment epithelium and age‑related 
macular degeneration. Bioorg Med Chem Lett. 2001;11:1533–40.
 27. Karan G, Lillo C, Yang Z, Cameron DJ, Locke KG, Zhao Y, Thirumalaichary S, 
Li C, Birch DG, Vollmer‑Snarr HR, et al. Lipofuscin accumulation, abnormal 
electrophysiology, and photoreceptor degeneration in mutant ELOVL4 
transgenic mice: a model for macular degeneration. Proc Natl Acad Sci 
USA. 2005;102:4164–9.
 28. Parish CA, Hashimoto M, Nakanishi K. Dillon J Sparrow J: Isolation and 
one‑step preparation of A2E and iso‑A2E, fluorophores from human 
retinal pigment epithelium. Proc Natl Acad Sci USA. 1998;95:14609–13.
 29. Dai Z, Lu L, Yang Z, Mao Y, Lu J, Li C, Qi W, Chen Y, Yao Y, Li L, et al. 
Kallikrein‑binding protein inhibits LPS‑induced TNF‑alpha by upregulat‑
ing SOCS3 expression. J Cell Biochem. 2013;114:1020–8.
 30. Zhang J, Yang Z, Li P, Bledsoe G, Chao L, Chao J. Kallistatin antagonizes 
Wnt/beta‑catenin signaling and cancer cell motility via binding to 
low‑density lipoprotein receptor‑related protein 6. Mol Cell Biochem. 
2013;379:295–301.
 31. Lu SL, Tsai CY, Luo YH, Kuo CF, Lin WC, Chang YT, Wu JJ, Chuang WJ, 
Liu CC, Chao L, et al. Kallistatin modulates immune cells and confers 
anti‑inflammatory response to protect mice from group A streptococcal 
infection. Antimicrob Agents Chemother. 2013;57:5366–72.
 32. McBride JD, Jenkins AJ, Liu X, Zhang B, Lee K, Berry WL, Janknecht R, 
Griffin CT, Aston CE, Lyons TJ, et al. Elevated circulation levels of an antian‑
giogenic SERPIN in patients with diabetic microvascular complications 
impair wound healing through suppression of Wnt signaling. J Invest 
Dermatol. 2014;134:1725–34.
 33. Park K, Lee K, Zhang B, Zhou T, He X, Gao G, Murray AR, Ma JX. Identifica‑
tion of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol. 
2011;31:3038–51.
 34. Zhou T, Hu Y, Chen Y, Zhou KK, Zhang B, Gao G, Ma JX. The pathogenic 
role of the canonical Wnt pathway in age‑related macular degeneration. 
Invest Ophthalmol Vis Sci. 2010;51:4371–9.
 35. Klaus A, Birchmeier W. Wnt signalling and its impact on development and 
cancer. Nat Rev Cancer. 2008;8:387–98.
 36. Logan CY, Nusse R. The Wnt signaling pathway in development and 
disease. Annu Rev Cell Dev Biol. 2004;20:781–810.
 37. Cerpa W, Toledo EM, Varela‑Nallar L, Inestrosa NC. The role of Wnt signal‑
ing in neuroprotection. Drug News Perspect. 2009;22:579–91.
 38. Hackam AS. The Wnt signaling pathway in retinal degenerations. IUBMB 
Life. 2005;57:381–8.
 39. Toledo EM, Colombres M, Inestrosa NC. Wnt signaling in neuroprotection 
and stem cell differentiation. Prog Neurobiol. 2008;86:281–96.
 40. Marchetti B, L’Episcopo F, Morale MC, Tirolo C, Testa N, Caniglia S, Serapide 
MF, Pluchino S. Uncovering novel actors in astrocyte‑neuron crosstalk in 
Parkinson’s disease: the Wnt/beta‑catenin signaling cascade as the com‑
mon final pathway for neuroprotection and self‑repair. Eur J Neurosci. 
2013;37:1550–63.
 41. Lee K, Shin Y, Cheng R, Park K, Hu Y, McBride J, He X, Takahashi Y, Ma JX. 
Receptor heterodimerization as a novel mechanism for the regulation of 
Wnt/beta‑catenin signaling. J Cell Sci. 2014;127:4857–69.
 42. Zhang B, Abreu JG, Zhou K, Chen Y, Hu Y, Zhou T, He X, Ma JX. Blocking 
the Wnt pathway, a unifying mechanism for an angiogenic inhibitor 
in the serine proteinase inhibitor family. Proc Natl Acad Sci USA. 
2010;107:6900–5.
 43. Cui L, Guan Y, Qu Z, Zhang J, Liao B, Ma B, Qian J, Li D, Li W, Xu GT, et al. 
WNT signaling determines tumorigenicity and function of ESC‑derived 
retinal progenitors. J Clin Invest. 2013;123:1647–61.
 44. Nussenblatt RB, Lee RW, Chew E, Wei L, Liu B, Sen HN, Dick AD, Ferris 
FL. Immune responses in age‑related macular degeneration and a pos‑
sible long‑term therapeutic strategy for prevention. Am J Ophthalmol. 
2014;158(5–11):e12.
 45. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular 
endothelial growth factors and angiogenesis in eye disease. Prog Retin 
Eye Res. 2003;22:1–29.
 46. Shen D, Cao X, Zhao L, Tuo J, Wong WT, Chan CC. Naloxone ameliorates 
retinal lesions in Ccl2/Cx3cr1 double‑deficient mice via modulation of 
microglia. Invest Ophthalmol Vis Sci. 2011;52:2897–904.
 47. Wang Y, Subramanian P, Shen D, Tuo J, Becerra SP, Chan CC. Pigment 
epithelium‑derived factor reduces apoptosis and pro‑inflammatory 
cytokine gene expression in a murine model of focal retinal degenera‑
tion. ASN Neuro. 2013;5:e00126.
 48. Ardeljan D, Wang Y, Park S, Shen D, Chu XK, Yu CR, Abu‑Asab M, Tuo J, 
Eberhart CG, Olsen TW, et al. Interleukin‑17 retinotoxicity is prevented 
by gene transfer of a soluble interleukin‑17 receptor acting as a cytokine 
blocker: implications for age‑related macular degeneration. PLoS One. 
2014;9:e95900.
 49. Wang Y, Abu‑Asab MS, Yu CR, Tang Z, Shen D, Tuo J, Li X, Chan CC. 
Platelet‑derived growth factor (PDGF)‑C inhibits neuroretinal apoptosis in 
a murine model of focal retinal degeneration. Lab Invest. 2014;94:674–82.
 50. Oguma K, Oshima H, Oshima M. Inflammation, tumor necrosis factor 
and Wnt promotion in gastric cancer development. Future Oncol. 
2010;6:515–26.
 51. Schon S, Flierman I, Ofner A, Stahringer A, Holdt LM, Kolligs FT, Herbst 
A. Beta‑catenin regulates NF‑kappaB activity via TNFRSF19 in colorectal 
cancer cells. Int J Cancer. 2014;135:1800–11.
 52. Chen M, Zhao J, Luo C, Pandi SP, Penalva RG, Fitzgerald DC, Xu H. Para‑
inflammation‑mediated retinal recruitment of bone marrow‑derived 
myeloid cells following whole‑body irradiation is CCL2 dependent. Glia. 
2012;60:833–42.
 53. Chen M, Luo C, Penalva R, Xu H. Paraquat‑induced retinal degeneration is 
exaggerated in CX3CR1‑deficient mice and is associated with increased 
retinal inflammation. Invest Ophthalmol Vis Sci. 2013;54:682–90.
 54. Ross RJ, Zhou M, Shen D, Fariss RN, Ding X, Bojanowski CM, Tuo J, Chan 
CC. Immunological protein expression profile in Ccl2/Cx3cr1 deficient 
mice with lesions similar to age‑related macular degeneration. Exp Eye 
Res. 2008;86:675–83.
 55. Popp N, Chu XK, Shen D, Tuo J, Chan CC. evaluating potential therapies 
in a mouse model of focal retinal degeneration with age‑related macular 
degeneration (AMD)‑like lesions. J Clin Exp Ophthalmol. 2013;4:1000296.
 56. Park KH, Choi AJ, Yoon J, Lim D, Woo SJ, Park SJ, Kim HC, Chung H. Wnt 
modulators in the aqueous humor are associated with outer retinal dam‑
age severity in patients with neovascular age‑related macular degenera‑
tion. Invest Ophthalmol Vis Sci. 2014;55:5522–30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
